Compugen (CGEN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CGEN Stock Forecast


Compugen stock forecast is as follows: an average price target of $4.00 (represents a 177.78% upside from CGEN’s last price of $1.44) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CGEN Price Target


The average price target for Compugen (CGEN) is $4.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 177.78% upside from CGEN's last price of $1.44.

CGEN Analyst Ratings


Buy

According to 3 Wall Street analysts, Compugen's rating consensus is 'Buy'. The analyst rating breakdown for CGEN stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Compugen Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 21, 2024Asthika GoonewardeneTruist Financial$4.00$1.74129.89%177.78%
May 20, 2024Stephen WilleyStifel Nicolaus$4.00$1.74129.89%177.78%
May 20, 2024Asthika GoonewardeneTruist Financial$5.00$1.74187.36%247.22%
Row per page
Go to

The latest Compugen stock forecast, released on May 21, 2024 by Asthika Goonewardene from Truist Financial, set a price target of $4.00, which represents a 129.89% increase from the stock price at the time of the forecast ($1.74), and a 177.78% increase from CGEN last price ($1.44).

Compugen Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$4.33
Last Closing Price$1.44$1.44$1.44
Upside/Downside-100.00%-100.00%200.69%

In the current month, the average price target of Compugen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Compugen's last price of $1.44. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Feb 08, 2023Jefferies-UnderperformDowngrade
Nov 15, 2022OppenheimerOutperformOutperformHold
Aug 08, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Feb 25, 2022OppenheimerOutperformOutperformHold
Feb 25, 2022SVB LeerinkOutperformOutperformHold
Row per page
Go to

Compugen's last stock rating was published by Jefferies on Feb 08, 2023. The company Downgrade its CGEN rating from "null" to "Underperform".

Compugen Financial Forecast


Compugen Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Dec 21Mar 18Mar 16Mar 15Mar 14Sep 13Mar 10Mar 02Mar 01Sep 00
Revenue-----------$10.00M$93.00K$513.00K$2.13M$1.59M$125.00K$2.81M$2.25M$1.43M
Avg Forecast$29.93M$26.77M$23.94M$21.41M$16.52M$1.28M$1.66M$2.42M$20.00M$3.75M$1.00M$18.09M$79.41K$425.00K$5.33M$1.32M$81.25K$3.98M$2.07M$1.18M
High Forecast$56.51M$50.55M$45.21M$40.44M$31.19M$2.42M$1.66M$4.58M$37.77M$7.08M$1.00M$21.71M$95.29K$510.00K$6.39M$1.59M$97.50K$4.78M$2.48M$1.42M
Low Forecast$3.34M$2.99M$2.67M$2.39M$1.85M$143.00K$1.66M$270.93K$2.23M$418.96K$1.00M$14.47M$63.53K$340.00K$4.26M$1.06M$65.00K$3.18M$1.65M$945.12K
# Analysts11112111211919181310197159
Surprise %-----------0.55%1.17%1.21%0.40%1.20%1.54%0.71%1.09%1.21%

Compugen's average Quarter revenue forecast for Dec 21 based on 1 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. CGEN's average Quarter revenue forecast represents a -90.00% decrease compared to the company's last Quarter revenue of $10.00M (Mar 18).

Compugen EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Dec 21Mar 18Mar 16Mar 15Mar 14Sep 13Mar 10Mar 02Mar 01Sep 00
# Analysts11112111211919181310197159
EBITDA----------$-8.78M$115.00K$-8.87M$-6.32M$-3.31M$-4.40M$-2.72M$-3.61M$-4.25M$-3.14M
Avg Forecast$-14.21M$-12.71M$-11.37M$-10.17M$-7.84M$-607.76K$-788.98K$-1.15M$-9.50M$-1.78M$-474.81K$162.82K$-7.22M$-4.77M$-705.60K$-3.82M$-1.20M$-3.38M$-2.15M$-2.21M
High Forecast$-1.59M$-1.42M$-1.27M$-1.14M$-876.70K$-67.90K$-788.90K$-128.64K$-1.06M$-198.93K$-474.81K$195.38K$-5.78M$-3.81M$-564.48K$-3.05M$-957.44K$-2.70M$-1.72M$-1.77M
Low Forecast$-26.83M$-24.00M$-21.47M$-19.20M$-14.81M$-1.15M$-789.06K$-2.17M$-17.93M$-3.36M$-474.81K$130.25K$-8.66M$-5.72M$-846.72K$-4.58M$-1.44M$-4.05M$-2.58M$-2.65M
Surprise %----------18.49%0.71%1.23%1.33%4.69%1.15%2.27%1.07%1.97%1.42%

1 analysts predict CGEN's average Quarter EBITDA for Dec 21 to be $-474.81K, with a high of $-474.81K and a low of $-474.81K. This is -512.88% lower than Compugen's previous annual EBITDA (Mar 18) of $115.00K.

Compugen Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Dec 21Mar 18Mar 16Mar 15Mar 14Sep 13Mar 10Mar 02Mar 01Sep 00
# Analysts11112111211919181310197159
Net Income----------$-8.38M$82.00K$-8.06M$-5.79M$928.00K$-4.74M$-2.72M$-3.15M$-3.56M$-4.01M
Avg Forecast$-8.08M$-8.08M$-8.98M$-8.08M$6.29M$-8.53M$-7.78M$-9.88M$9.28M$-8.98M$-11.90M$180.91K$-7.45M$-4.91M$-2.74M$-3.79M$-1.20M$-4.08M$-3.29M$-2.21M
High Forecast$1.25M$1.25M$1.39M$1.25M$15.51M$1.32M$1.20M$1.53M$52.90M$1.39M$-11.90M$217.09K$-5.96M$-3.93M$-2.19M$-3.03M$-957.44K$-3.26M$-2.63M$-1.77M
Low Forecast$-17.42M$-17.42M$-19.35M$-17.42M$-2.93M$-18.39M$-16.77M$-21.29M$-12.99M$-19.35M$-11.90M$144.73K$-8.94M$-5.89M$-3.28M$-4.55M$-1.44M$-4.89M$-3.94M$-2.65M
Surprise %----------0.70%0.45%1.08%1.18%-0.34%1.25%2.27%0.77%1.08%1.82%

Compugen's average Quarter net income forecast for Dec 21 is $-11.90M, with a range of $-11.90M to $-11.90M. CGEN's average Quarter net income forecast represents a -14606.36% decrease compared to the company's last Quarter net income of $82.00K (Mar 18).

Compugen SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Dec 21Mar 18Mar 16Mar 15Mar 14Sep 13Mar 10Mar 02Mar 01Sep 00
# Analysts11112111211919181310197159
SG&A----------$2.94M$2.47M$2.11M$1.67M$1.45M$1.69M$1.21M$2.40M$2.50M$1.54M
Avg Forecast$60.37M$54.00M$48.30M$43.20M$33.32M$2.58M$3.35M$4.89M$40.35M$7.56M$2.01M$4.46M$159.97K$856.12K$2.08M$2.67M$163.67K$3.21M$4.17M$2.38M
High Forecast$114.00M$101.97M$91.20M$81.57M$62.92M$4.88M$3.35M$9.24M$76.18M$14.28M$2.01M$5.35M$191.96K$1.03M$2.50M$3.20M$196.40K$3.85M$5.00M$2.86M
Low Forecast$6.75M$6.03M$5.40M$4.83M$3.72M$288.48K$3.35M$546.52K$4.51M$845.14K$2.01M$3.57M$127.97K$684.90K$1.67M$2.14M$130.94K$2.57M$3.33M$1.90M
Surprise %----------1.46%0.55%13.18%1.95%0.69%0.63%7.38%0.75%0.60%0.65%

Compugen's average Quarter SG&A projection for Sep 23 is $7.56M, based on 1 Wall Street analysts, with a range of $845.14K to $14.28M. The forecast indicates a 157.57% rise compared to CGEN last annual SG&A of $2.94M (Dec 21).

Compugen EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Dec 21Mar 18Mar 16Mar 15Mar 14Sep 13Mar 10Mar 02Mar 01Sep 00
# Analysts11112111211919181310197159
EPS----------$-0.10-$-0.16$-0.11$-0.04$-0.12$-0.08$-0.12$-0.14$-0.24
Avg Forecast$-0.09$-0.09$-0.10$-0.09$0.07$-0.10$-0.09$-0.11$0.10$-0.10$-0.13$-0.34$-0.13$-0.08$-0.14$-0.08$-0.02$-0.22$-0.12$-0.09
High Forecast$0.01$0.01$0.02$0.01$0.17$0.01$0.01$0.02$0.59$0.02$-0.13$-0.27$-0.10$-0.06$-0.12$-0.06$-0.02$-0.18$-0.10$-0.07
Low Forecast$-0.19$-0.19$-0.22$-0.19$-0.03$-0.20$-0.19$-0.24$-0.14$-0.22$-0.13$-0.41$-0.16$-0.10$-0.17$-0.10$-0.03$-0.26$-0.14$-0.11
Surprise %----------0.74%-0.00%1.23%1.38%0.29%1.50%4.12%0.55%1.17%2.67%

According to 1 Wall Street analysts, Compugen's projected average Quarter EPS for Dec 21 is $-0.13, with a low estimate of $-0.13 and a high estimate of $-0.13. This represents a -8403.75% decrease compared to CGEN previous annual EPS of - (Mar 18).

Compugen Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ALLOAllogene Therapeutics$2.12$29.001267.92%Buy
EVGNEvogene$1.73$12.00593.64%Buy
EDITEditas Medicine$2.48$12.85418.15%Buy
ITOSiTeos Therapeutics$7.90$37.67376.84%Buy
SANASana Bio$2.36$8.00238.98%Buy
CLGNCollPlant Bio$4.19$14.00234.13%Buy
CGENCompugen$1.44$4.00177.78%Buy
ANNXAnnexon$5.46$14.00156.41%Buy
BEAMBeam Therapeutics$25.29$58.50131.32%Buy
CRBUCaribou Biosciences$1.99$3.0050.75%Buy
VECTVectivBio$16.87$18.006.70%Buy

CGEN Forecast FAQ


Is Compugen a good buy?

Yes, according to 3 Wall Street analysts, Compugen (CGEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CGEN's total ratings.

What is CGEN's price target?

Compugen (CGEN) average price target is $4 with a range of $4 to $4, implying a 177.78% from its last price of $1.44. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Compugen stock go up soon?

According to Wall Street analysts' prediction for CGEN stock, the company can go up by 177.78% (from the last price of $1.44 to the average price target of $4), up by 177.78% based on the highest stock price target, and up by 177.78% based on the lowest stock price target.

Can Compugen stock reach $2?

CGEN's average twelve months analyst stock price target of $4 supports the claim that Compugen can reach $2 in the near future.

What are Compugen's analysts' financial forecasts?

Compugen's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21.88M (high $39.85M, low $3.92M), average EBITDA is $-10.391M (high $-1.862M, low $-18.92M), average net income is $-19.91M (high $19.56M, low $-59.383M), average SG&A $44.15M (high $80.38M, low $7.91M), and average EPS is $-0.222 (high $0.218, low $-0.661). CGEN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $102.05M (high $192.71M, low $11.4M), average EBITDA is $-48.457M (high $-5.414M, low $-91.5M), average net income is $-33.233M (high $5.14M, low $-71.61M), average SG&A $205.87M (high $388.74M, low $23M), and average EPS is $-0.37 (high $0.0573, low $-0.797).

Did the CGEN's actual financial results beat the analysts' financial forecasts?

Based on Compugen's last annual report (Dec 2021), the company's revenue was $6M, beating the average analysts forecast of $1M by 500.00%. Apple's EBITDA was $-35.074M, beating the average prediction of $-475K by 7286.91%. The company's net income was $-32.461M, beating the average estimation of $-11.895M by 172.89%. Apple's SG&A was $11.7M, beating the average forecast of $2.01M by 480.82%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.133 by 193.54%. In terms of the last quarterly report (Mar 2018), Compugen's revenue was $10M, missing the average analysts' forecast of $18.09M by -44.72%. The company's EBITDA was $115K, missing the average prediction of $162.82K by -29.37%. Compugen's net income was $82K, missing the average estimation of $180.91K by -54.67%. The company's SG&A was $2.47M, missing the average forecast of $4.46M by -44.68%. Lastly, the company's EPS was $0.0016, missing the average prediction of $-0.34 by -100.47%